Table of Contents
Executive Summary
- An introduction to combination products
- Combination product strategies in the cardiovascular market
- Combination product strategies in the respiratory market
- Combination product strategies in the diabetes market
- Combination product strategies in the HIV market
- Combination product strategies in the women' s health market
- Combination product strategies in other therapeutic markets
- Brand extension and franchise development strategies
Chapter 1 An introduction to combination products
- Summary
- Introduction
- Therapeutic value
- Combining therapies
- Improved convenience
- Commercial value
- Brand extension
- Franchise development
- Leading combination products
- Key products
- Key therapeutic categories
- Key combination product strategies
Chapter 2 Strategies for cardiovascular products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Exforge
- Future combination product developments
- Simcor
- Avandia/simvastatin
- Key combination product launch strategies
Chapter 3 Strategies for respiratory products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Symbicort
- Future combination product developments
- Singulair/Claritin
- Flutiform
- Key combination product launch strategies
Chapter 4 Strategies for diabetes products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Janumet
- Duetact
- Future combination product developments
- Avandia/simvastatin
- Synordia
- Key combination product launch strategies
Chapter 5 Strategies for HIV products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Atripla
- Future combination product developments
- Key combination product launch strategies
Chapter 6 Strategies for women' s health
- products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Lybrel
- Angeliq
- Future combination product developments
- Aprela
- DUB-OC
- Key combination product launch strategies
Chapter 7 Strategies for other therapeutic areas
- Summary
- Introduction
- Leading combination products
- Anti-infectives
- Recent combination product launches
- Combigan
- Ziana
- Pylera
- Future combination product developments
- Oncology
- CNS and pain
- Key combination product launch strategies
Chapter 8 Brand extension and franchise development strategies
- Summary
- Introduction
- Case studies
- Diovan, Diovan HCT/Co-Diovan and Exforge
- Avandia, Avandamet and Avandaryl
- Advair/Seretide
- Case study: Kaletra
- Case study: Vytorin
- Key success factors
- Branding
- Pricing
- Positioning
Chapter 9 Appendix
- Sources
- Product sales data
- Regulatory data
- Specific sources
List of Figures
- Figure 1.1: Number of combination products by therapy area, 2006
- Figure 1.2: Key combination product strategies
- Figure 2.3: Key cardiovascular combination product strategies
- Figure 3.4: Key respiratory combination product strategies
- Figure 4.5: Key diabetes combination product strategies
- Figure 6.6: Key women' s health combination product strategies
- Figure 8.7: Diovan, Diovan HCT/Co-Diovan sales, 2002-2006
- Figure 8.8: Avandia, Avandamet and Avandaryl sales, 2002-2006
- Figure 8.9: Advair/Seretide, Flovent/Flixotide and Serevent sales,
2002-2006
- Figure 8.10: Kaletra sales, 2002-2006
- Figure 8.11: Vytorin, Zetia and Zocor sales, 2002-2006
List of Tables
- Table 1.1: Leading brand extension combination products, 2006
- Table 1.2: Leading brand extension combination products, 2006
- Table 1.3: Leading franchise development combination products, 2006
- Table 2.4: Leading brand extension combination products in the
cardiovascular market, 2004-2006
- Table 2.5: Leading franchise development combination products in the
cardiovascular market, 2004-2006
- Table 2.6: Recently approved combination products in the cardiovascular
market, 2005-2007
- Table 2.7: Future combination products in development for the
cardiovascular market, 2007
- Table 3.8: Leading brand extension combination products in the respiratory
market, 2004-2006
- Table 3.9: Leading franchise development combination products in the
respiratory market, 2004-2006
- Table 3.10: Recently approved combination products in the respiratory
market, 2005-2007
- Table 3.11: Future combination products in development for the respiratory
market, 2007
- Table 4.12: Leading brand extension combination products in the diabetes
market, 2004-2006
- Table 4.13: Recently approved combination products in the diabetes market,
2005-2007
- Table 4.14: Future combination products in development for the diabetes
market, 2007
- Table 5.15: Leading franchise development combination products in the HIV
market, 2004-200660
- Table 5.16: Recently approved combination products in the HIV market,
2005-2007
- Table 6.17: Leading brand extension combination products in the women' s
health market, 2004-2006
- Table 6.18: Leading franchise development combination products in the
women' s health market, 2004-2006
- Table 6.19: Recently approved combination products in the women' s health
market, 2005-2007
- Table 6.20: Future combination products in development for the women' s
health market, 2007
- Table 7.21: Leading brand extension combination products in other
therapeutic markets, 2004-2006
- Table 7.22: Leading franchise development combination products in other
therapeutic markets, 2004-2006
- Table 7.23: Recently approved combination products in other therapeutic
markets, 2005-2007
- Table 7.24: Future combination products in development for other
therapeutic markets, 2007
|
Related Report
|
View Cart
